. . . . . . "drugbank_resource:DB00582_DB01072" . "DDI between Voriconazole and Atazanavir - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."@en . . "DDI between Voriconazole and Atazanavir - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. [drugbank_resource:DB00582_DB01072]"@en . . "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" . "MC0CFQCO3hVRMgo8VA2vAI2V4KN2hYWJZAIUTM1nhkQB02lGq6aPGO21hKcrgHY=" . . "2018-03-30T11:13:15.567+02:00"^^ . . . . . . "3c184e6c-ceb8-4275-a679-71dfbdac2a11" . . . . . "eda7951a5f6c622c5d2132f50c3093138484a349" . .